AIDS
Conditions
Interventions
Experimental group:Swith to BIC/F/TAF
Control group:NA
Sponsors
Beijing Ditan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Sign a written informed consent form (adolescent and/or their legal guardian); 2. 12 to 18 years old and weight >= 35kg; 3. Confirmed HIV antibody positive through western blot testing; 4. On current standard triple therapy regimens for > 48weeks, HIV RNA = 50ml/min (calculated by CKD EPI); 6. There were no clear or suspected drug resistance record to ntritabine (FTC), tenofovir (TFV) or integrase chain transtransfer inhibitor (INST), including but not limited to reverse transcriptase resistance mutations K65R and M184V/I.
Exclusion criteria
Exclusion criteria: 1. A new AIDS defining condition diagnosed within the 30 days prior to screening; 2. Participants receiving ongoing therapy contradicted to use BIC/F/TAF or participants with any known allergies to the components of BIC/F/TAF; 3. Severe hepatic impairment (Child Pugh C); 4. Any other clinical condition or prior therapy that, in the opinion of the Investigator, would make the subject unsuitable for the study or unable to comply with dosing requirements; 5. Participants with any documented history of virological failure (confirmed VL> 200 copies/ml), or history of resistance to any nucleoside reverse transcriptase inhibitors. * The standard triple therapy regimen contained two NRTIs + NNRTI or two NRTIs +PI.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HIV-RNA;CD4+T Cell;Blood routine;Blood chemistry;Bone Mass Measurement; | — |
Countries
China
Contacts
Public ContactFujie Zhang
Beijing Ditan Hospital, Capital Medical University
Outcome results
None listed